Abstract
This introductory article to the review series entitled “The Cancer Cell’s Power Plants as Promising Therapeutic Targets” is written while more than 20 million people suffer from cancer. It summarizes strategies to destroy or prevent cancers by targeting their energy production factories, i.e., “power plants.” All nucleated animal/human cells have two types of power plants, i.e., systems that make the “high energy” compound ATP from ADP and P i . One type is “glycolysis,” the other the “mitochondria.” In contrast to most normal cells where the mitochondria are the major ATP producers (>90%) in fueling growth, human cancers detected via Positron Emission Tomography (PET) rely on both types of power plants. In such cancers, glycolysis may contribute nearly half the ATP even in the presence of oxygen (“Warburg effect”). Based solely on cell energetics, this presents a challenge to identify curative agents that destroy only cancer cells as they must destroy both of their power plants causing “necrotic cell death” and leave normal cells alone. One such agent, 3-bromopyruvate (3-BrPA), a lactic acid analog, has been shown to inhibit both glycolytic and mitochondrial ATP production in rapidly growing cancers (Ko et al., Cancer Letts., 173, 83–91, 2001), leave normal cells alone, and eradicate advanced cancers (19 of 19) in a rodent model (Ko et al., Biochem. Biophys. Res. Commun., 324, 269–275, 2004). A second approach is to induce only cancer cells to undergo “apoptotic cell death.” Here, mitochondria release cell death inducing factors (e.g., cytochrome c). In a third approach, cancer cells are induced to die by both apoptotic and necrotic events. In summary, much effort is being focused on identifying agents that induce “necrotic,” “apoptotic” or apoptotic plus necrotic cell death only in cancer cells. Regardless how death is inflicted, every cancer cell must die, be it fast or slow.
Article PDF
Similar content being viewed by others
References
Aisenberg AC (1961) The glycolysis and respiration of tumors. Academic Press, New York and London Part II: The Oxidative Metabolism of Tumors, pp 156–157
Allison PD (1995) In: Survival analysis using SAS, A practical guide, Chapter 3, SAS Publishing, Cary, North Carolina, pp 30–32
Andre N, Rome A, Carre M (2006) Archives de Pediatrie 13:69–75
Arora KK, Pedersen PL (1988) J Biol Chem 263:17422–17428
Arunkumar A, Vijayababu MR, Gunadharini N, Krishnamoorthy G, Arunakaran J (2006) Cancer Lett. Epub ahead of print
Athanasiou A, Smith PA, Vakilpour S, Kumaran NM, Turner AE, Bagiokou D, Layfield R, Ray DE, Westwell AD, Alexander SP, Kendall DA, Lobo DN, Watson SA, Lophatanon A, Muir KA, Guo DA, Bates TE (2007) Biochem Biophys Res Commun 354:50–55
Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B (2006) Clin Lymphoma Myeloma 7:210–216
Barna G, Sebestyen A, Weischede S, Petak I, Mihalik R, Formelli F, Kopper L (2005) Anticancer Res 25:4179–4185
Bleday R, Weiss MJ, Salem RR, Wilson RE, Chen LB, Steele G Jr (1986) Arch Surg 121:1272–1275
Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED (2007) Cancer Cell 11:37–51
Bouchier-Hayes L, Lartigue L, Newmeyer DD (2005) J Clin Invest 115:2640–2647
Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, VonHoff DD, Eckhardt SG (2000) Clin Cancer Res 6:42–49
Bustamante E, Pedersen PL (1977) Proc Natl Acad Sci (USA) 74:3735–3739
Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, Coll-Mulet L, de Frias M, Domingo A, Pons G, Gil J (2006) Exp Hematol 34:1663–1669
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M (2006) Blood 108:630–637
Cereghetti GM, Scorrano L (2006) Oncogene 25:4717–4724
Chen BJ (2001) Leuk Lymphoma 42:253–265
Chen J, Ramos J, Sirisawad M, Miller R, Naumovski L (2005) Apoptosis 10:1131–1142
Chen LB (1989) Methods Cell Biol 29:103–123
Cherry SR (2006) J Nuc Med 47:1735–1745
Chitambar CR, Wereley JP, Matsuyama SM (2006) Cancer Ther 5:2834–2843
Dancy J, Sausville EA (2003) Nat Rev Drug Discov 2:296–313
Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A (2007) J Clin Invest 117:112–121
Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F (2003) Drugs Today (Barc) 39:157–174
Don AS, Hogg PJ (2004) Trends Mol Med 10:372–378
Efferth T (2006) Curr Drug Targets 7:407–421
Eggermont AM (2006) J Clin Oncol 24:4673–4674
El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA (2005) Int J Cancer 117:409–417
Elshimali YI, Grody WW (2006) Diagn Mol Pathol 15:187–194
Engel M, Mazurek S, Eingenbrodt E, Welter CJ (2004) J Biol Chem 279:35803–35812
Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) Mol Pharm 70:2108–2115
Farber S (1950) Am J Dis Child 79:961–962
Fischer OM, Streit S, Hart S, Ullrich A (2003) Curr Opin Chem Biol 7:490–495
Fleming A (1929) Br J Exp Pathol 10:226–236
Foubister V (2002) DDT 7:934–935
Frankel SR (2003) Semin Oncol 30:300–3004
Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, Schneider-Stock R (2004) Int J Oncol 25:858–866
Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006) Oncogene 25:4812–4830
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Cancer Res 62:3903–3913
Goodsell DS (2004) The Oncologist 9:226–227
Greville G (1969) Curr Top Bioenerg 3:1–78
Hosler JP, Ferguson-Miller S, Mills DA (2006) Annu Rev Biochem 75:165–187
Issat T, Jakobisiak M, Golab J (2006) Oncol Rep 16: 1273–1276
Jiang X, Wang X (2004) Annu Rev Biochem 73:87–106
Johnson JH, Belt JA, Dubinsky WP, Zimniak A, Racker E(1980) Biochemistry 19:3836–3840
Johnson LV, Johnson ML, Chen LB (1980) Proc Natl Acad Sci (USA) 77:990–994
Kerkela R, Grazette L, Yacobi R, Iliescu C, Pattern R, Beahm C, Walters G, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, A Van Hatten R, Alroy J, Durand J-B, Force T (2006) Nat Med 12:908–916
Kerr JF, Wyllie AH, Currie AR (1972) Br J Cancer 26:239–257
Ko JK, Leung WC, Ho WK, Chiu P (2006) Eur J Pharmacol [Epub ahead of print]
Ko YH, Pedersen PL, Geschwind (2001) Cancer Lett 173:83–91
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Biochem Biophys Res Commun 324:269–275
Koya K, Li Y, Wang H, Ukai T, Tatsukta N, Kawakami M, Shishido, Chen LB (1996) Cancer Res 56:538–543
LeBras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouilat D, Lemaire C, Kroemer G, Jacotot E, Brenner C (2006) Cancer Res 66:9143–9152
Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK (2002) Life Sci 71:2729–2740
Malhi H, Gores GJ, Lemasters JJ (2006) Hepatology 43:S31–S44
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) Science 298:1912–1934
Marcinkowska A, Malarska A, Saczko J, Chwilkowska A, Wysocka T, Drag-Zalesinska M, Wysocka T, Banas T (2001) Folia Histochem Cytobiol 39(Suppl 2):177–178
Mathupala SP, Ko YH, Pedersen PL (2006) Oncogene 25:4777–4786
Mathupala SP, Parajuli P, Sloan AE (2004) Neurosurgery 55:1410–1419
McGuire JJ (2003) Curr Pharm Design 9:2593–2613
Mitchell P (1961) Nature 191:144–148
Nakashima RA, Paggi MG, Pedersen PL (1984) Cancer Res 44:5702–5706
Nakashima RA, Managan PS, Colombini M, Pedersen PL (1986) Biochemistry 25:1015–1021
Neuzil J, Wang X-F, Dong L-F, Low P, Ralph SJ (2006) FEBS Lett 580:5125–5129
Niizuma H, Nakamura Y, Ozaki T, Nakanishi H, Ohira M, Isogai E, Kageyama H, Imaizumi M, Nakagawara A (2006) Oncogene 25:5046–5055
Oh KW, Qian T, Brenner DA, Lemaster JJ (2003) Toxicol Sci 73:44–52
Palozza P, Serini S, Torsello A, Dinicuolo F, Maggiano N, Ranelletti FO, Wolf FI, Calviello G (2003) Nutr Cancer 47:76–87
Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S (2006) Anticancer Res 26(1A):259–265
Pastorino JG, Shulga N, Hoek JB (2002) J Biol Chem 277:7610–7618
Pedersen PL (1978) Prog Exp Tumor Res 22:190–274
Pelicano H, Martin DS, Xu R-H, Huang P (2006) Oncogene 25:4633–4646
Perchellet EM, Wang Y, Weber RL, Lou K, Hua DH, Perchellet JP (2004) Anticancer Drugs 15:929–946
Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, A Van Hatten R, Alroy J, Durand J-B, Force T (2006) Nat Med 12:908–916
Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogus G, Ponzoni M, Rozzo C (2007) Mol Cancer 6:8
Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, Li LC, Dahiya R (2007) Biochem Biophys Res Commun 354:852–857
Rall TW, Sutherland EW (1958) J Biol Chem 232:1065–1076
Richards GM, Mehta MP (2007) Expert Opin Pharmacother 8:351–359
Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC (2006) Curr Pharm Biotechnol 7:441–448
Rzeski W, Stepulak A, Szymanski M, Sifringer M, Kaczor J, Wejksza K, Zdzisinka B, Kandefer-Szerszen M (2006) Naunyn Schmiedebergs Arch Pharmol 374:11–20
Sancho P, Galeano E, Nieto E, Delgado MD, Garcia-Perez AI (2007) Leukema Research (On Line)
Schreiber JR, Balcavage WX, Morris HP, Pedersen PL (1970) Cancer Res 30:2497–2501
Shen PF (2004) Front Biosci 9:2663–2670
Shields AF (2006) Mol Imaging Biol 8:141–150
Spencer TL, Lehninger AL (1976) Biochem J 154:405–414
Strebhardt K, Ullrich A (2006) N Eng J Med 355:2481–2482
Sun X, Wong JR, Song K, Hu J, Garlid KD, Chen LB (1994) Cancer Res 54:1465–1471
Sutherland EW, Rall TW (1958) J Biol Chem 232:1077–1092
Tang L, Jin T, Zeng X, Wang JS (2005) J Nutr 135:287–290
Wang Y, Perchellet EM, Ward MM, Lou K, Zhao H, Battina SK, Wiredu B, Hua DH, Perchellet JP (2006b) Int J Oncol 28:161–172
Wang XS, Yang W, Tao SJ, Li K, Li M, Dong JH, Wang MH (2006a) Yakuqaku Zasshi 126:979–990
Warburg O (1930) The metabolism of tumors. Constable, London
Weber G (1968) Naturwissenschaften 55:418–429
Weber G (2001) Biochem (Mosc) 66(10):1164–1173
Weber G, Lea MA (1966) Adv Enzyme Regul 4:115–145
Weinhouse S (1972) Cancer Res 32:2007–2016
Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr, Chen LB (1987) Proc Natl Acad Sci 84:5444–5448
Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr (1988) Annu Rev Cell Biol 4:155–181
Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P (2005) Leukemia 19:2153–2158
Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P (2006) Anticancer Res 26: 3561–3566
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pedersen, P.L. The cancer cell’s “power plants” as promising therapeutic targets: An overview. J Bioenerg Biomembr 39, 1–12 (2007). https://doi.org/10.1007/s10863-007-9070-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-007-9070-5